{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:25:34Z","timestamp":1791300334632,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary and secondary myelofibrosis (MF), are known to have an increased risk of second malignancies (SMs). Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs. Controversy exists as to whether HU use is associated with a higher risk of SMs, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We conducted a retrospective cohort study of older patients diagnosed with MPN (age \u226566 years) between 2010 and 2017 and included the data in the Surveillance, Epidemiology, and End Results Medicare-linked database. Multivariable competing risk analyses adjusting for patient characteristics were used to assess the impact of HU on the development of SM. We identified 4023 patients (1688 with PV, 1976 with ET, and 359 with MF) with a median age of 77 (interquartile range [IQR], 71-83) years at the time of MPN diagnosis. After a median follow-up of 3.25 (IQR, 2.10-5.00) years, 489 patients developed an SM (346 solid, 73 lymphoid, and 70 myeloid malignancies). The cumulative incidence probability of SM was 19.88% (95% confidence interval [CI], 17.16%-22.75%) among 2683 HU users and 22.31% (95% CI, 17.51%-27.47%) among 1340 nonusers, respectively (Gray\u2019s test, P\u00a0&amp;lt; .01). We did not identify significant differences in the incidence of solid or hematologic SMs, including AML\/MDS (hazard ratio, 1.33; 95% CI, 0.77-2.29; P\u00a0= .30), between HU users and nonusers. Our results suggest that the use of HU does not increase the risk of SM in older patients with MPN.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008259","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T19:08:50Z","timestamp":1659467330000},"page":"734-743","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea"],"prefix":"10.1182","volume":"7","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"2Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8542-2944","authenticated-orcid":false,"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Stempel","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"2Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT"},{"name":"3Department of Internal Medicine (Hematology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"20","key":"2023081515545477300_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2023081515545477300_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"2023081515545477300_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2023081515545477300_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023081515545477300_bib5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2023081515545477300_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"2023081515545477300_bib7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"2023081515545477300_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.leukres.2015.05.002","article-title":"Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: clinical characteristics, therapy and outcome","volume":"39","author":"Masarova","year":"2015","journal-title":"Leuk Res"},{"issue":"4","key":"2023081515545477300_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1179\/102453308X316022","article-title":"Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution","volume":"13","author":"Radaelli","year":"2008","journal-title":"Hematology"},{"issue":"2","key":"2023081515545477300_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2010.08538.x","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa","volume":"153","author":"Fallah","year":"2011","journal-title":"Br J Haematol"},{"issue":"25","key":"2023081515545477300_bib11","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2023081515545477300_bib12","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023081515545477300_bib13","first-page":"1197","article-title":"A\u00a0population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2023081515545477300_bib14","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"2023081515545477300_bib15","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2023081515545477300_bib16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"2023081515545477300_bib17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"2023081515545477300_bib18","unstructured":"National Comprehensive Cancer Network\n          . Myeloproliferative neoplasms (version 2). Accessed 29 April 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"issue":"3","key":"2023081515545477300_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2018.7095","article-title":"Impact of hydroxyurea on survival and risk of thrombosis among older patients with essential thrombocythemia","volume":"17","author":"Podoltsev","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"20","key":"2023081515545477300_bib20","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/bloodadvances.2018021436","article-title":"The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera","volume":"2","author":"Podoltsev","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2023081515545477300_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","article-title":"Hydroxycarbamide: a user\u2019s guide for chronic myeloproliferative disorders","volume":"11","author":"Spivak","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2023081515545477300_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","article-title":"Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"52","author":"Nand","year":"1996","journal-title":"Am J Hematol"},{"issue":"9","key":"2023081515545477300_bib23","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","article-title":"Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis","volume":"101","author":"Finazzi","year":"2003","journal-title":"Blood"},{"issue":"17","key":"2023081515545477300_bib24","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023081515545477300_bib25","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"1","key":"2023081515545477300_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ejh.12787","article-title":"Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Hansen","year":"2017","journal-title":"Eur J Haematol"},{"issue":"2","key":"2023081515545477300_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0609.1992.tb00580.x","article-title":"Multiple skin tumors in long-term treatment with hydroxyurea","volume":"48","author":"Stasi","year":"1992","journal-title":"Eur J Haematol"},{"issue":"10","key":"2023081515545477300_bib28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4065\/73.10.961","article-title":"Multiple skin cancers associated with hydroxyurea therapy","volume":"73","author":"Best","year":"1998","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2023081515545477300_bib29","first-page":"e13043","article-title":"Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience","volume":"32","author":"Cantisani","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023081515545477300_bib30","unstructured":"Overview of the SEER Program. 2019. Accessed 15 October 2019. https:\/\/seer.cancer.gov\/about\/overview.html."},{"issue":"5","key":"2023081515545477300_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/pros.23281","article-title":"Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study","volume":"77","author":"Wang","year":"2017","journal-title":"Prostate"},{"issue":"1","key":"2023081515545477300_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jnci\/djs463","article-title":"Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity","volume":"105","author":"Yu","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"2023081515545477300_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A\u00a0novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"1","key":"2023081515545477300_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10552-013-0310-1","article-title":"Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"8","key":"2023081515545477300_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"12","key":"2023081515545477300_bib36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"2023081515545477300_bib37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2023081515545477300_bib38","unstructured":"European Medicines Agency\n          . Besremi. Accessed 5 July 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besremi."},{"key":"2023081515545477300_bib39","unstructured":"US Food and Drug Administration\n          . FDA approves treatment for rare blood disease. Accessed 5 July 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease."},{"issue":"4","key":"2023081515545477300_bib40","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"29","key":"2023081515545477300_bib41","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023081515545477300_bib42","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/734\/2071217\/blooda_adv-2022-008259-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/5\/734\/2071217\/blooda_adv-2022-008259-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T16:06:51Z","timestamp":1692115611000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/5\/734\/486087\/Second-malignancies-among-older-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008259","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}